The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

The FDA has determined that the nationwide shortage of semaglutide injection, used for both diabetes and weight loss, is resolved after more than two years of limited availability due to high demand.

The Food and Drug Administration said on Friday that the shortage of semaglutide injection products, such as Novo Nordisk's Wegovy, has been resolved. FDA's update led to renewed uncertainty for a ...

Taking semaglutide may lead to a slight increase in heart rate — typically by two to three beats per minute, based on trials sponsored by Novo Nordisk using 0.5 and 1 mg doses of semaglutide.

Still, the findings suggest semaglutide could play a role in reshaping addiction treatment. According to the National Institutes of Health, only three medications are currently FDA-approved to ...

The SELECT trial findings revealed that non-diabetic, overweight, and obese adults taking semaglutide (2.4 mg) for more than three years are at 20% less risk of stroke, heart attack, or death ...